STENOCARE A/S (STENOCARE or the “Company”) published on August 21st the Company’s Q2-report for 2025.

The following are some key points that we have chosen to highlight in connection with the report:

• Strong sales momentum in Denmark
• Astrum oil is now available in three countries
• Reaches positive EBITDA – above our expectations
• Stable cash position following capital raise

In summary, STENOCARE’s Q2 2025 report demonstrates strong progress, with net sales increasing by 131% despite a more conservative revenue recognition method and EBITDA turning positive for the first time since 2019. The growth was primarily driven by higher sales in Denmark, while the launch of Astrum Oil in Germany, Australia, and Norway provides additional long-term growth potential as market penetration advances. The successful execution of the STENOCARE 3.0 strategy, including a significant cost reduction and transition to a trading-based business model, has strengthened profitability faster than expected. Combined with a stable cash position and continued sales momentum, Analyst Group views positively on STENOCARE’s ability to further improve profitability and move towards sustained positive cash flow.

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group

This is a press release from Analyst Group regarding the publication of a comment on Stenocare. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.

Läs mer på MFN